Latest Breaking News On - Pivotal trial - Page 1 : comparemela.com

Bladder Cancer: Long-Term Benefits of Blue Light Cystoscopy and Enhanced Detection with HD Technology Unveiled at AUA 2024

/PRNewswire/ Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces its participation in the congress, and two abstract presentations at the AUA.

Chile
Israel
Oslo
Norway
San-antonio
Texas
United-states
New-zealand
Hailong
Yunnan
China
Canada

Photocure: Bladder Cancer: Long-Term Benefits of Blue Light Cystoscopy and Enhanced Detection with HD Technology Unveiled at AUA 2024

Photocure: Bladder Cancer: Long-Term Benefits of Blue Light Cystoscopy and Enhanced Detection with HD Technology Unveiled at AUA 2024
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Chile
Israel
United-states
Australia
Oslo
Norway
Canada
China
San-antonio
Texas
Hailong
Yunnan

Ablative Solutions' TARGET BP I Pivotal Trial Results Demonstrate Significant Reduction in 24-Hour Ambulatory Systolic Blood Pressure Compared to Sham, Using Alcohol-Mediated Renal Denervation

/PRNewswire/ Ablative Solutions, Inc., announced that primary trial results from the TARGET BP I Pivotal Trial, evaluating alcohol-mediated renal.

United-states
Kate-rumrill
David-kandzari
Ablative-solutions
American-college-of-cardiology
Scientific-congress
Piedmont-heart-institute
Prnewswire-ablative-solutions-inc
Ablative-solutions-inc
Late-breaking-clinical-trial
Primary-endpoint
Uncontrolled-hypertension

Protembis GmbH: Protembis Announces First Patient Enrolled in the PROTEMBO IDE Pivotal Trial

Protembis GmbH: Protembis Announces First Patient Enrolled in the PROTEMBO IDE Pivotal Trial
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United-states
Boston
Massachusetts
Germany
Stephan-haussig-herzzentrum
Conrad-rasmus-karl
Dennis-riedl
Protembis-gmb
Raj-makkar-cedars
Roxana-mehran-mount
Los-angeles
Protembis-gmbh

Protembis Announces First Patient Enrolled in the PROTEMBO IDE Pivotal Trial

NEW YORK & AACHEN, Germany, April 02, 2024 Protembis GmbH (Protembis), a privately-held emerging cardiovascular medical device company, announced today the enrollment of the first patient in the PROTEMBO Investigational Device Exemption (IDE) Pivotal Trial (NCT05873816). The trial will enroll between 250-500 randomized patients undergoing transcatheter aortic valve replacement (TAVR) in the USA and Europe with the ProtEmbo® System, an innovative next generation cerebral embolic protection devic

Germany
United-states
Boston
Massachusetts
Roxana-mehran-mount
Conrad-rasmus-karl
Raj-makkar-cedars
Los-angeles
Protembis-gmbh
Stephan-haussig-herzzentrum
Protembis-gmb
Global-co